CCR5-001

N/A

Report date: 2024/04/17 10:52:19

First In Class

Base Information

Drug NameCCR5-001

Drug Alias NameCCR5 targeting oncology drug-FC conjugate (Cidara Therapeutics)CCR5-001CCR5-DFC

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionC-C chemokine receptor type 5 modulators

TargetsC-C chemokine receptor type 5

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCidara Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCidara Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A